257 completed, 63 terminated, 27 unknown, 23 recruiting. 192 Phase 1, 160 Phase 2, 29 Not applicable, 23 Phase 3, 8 Early Phase 1.
Follow Oligodendroglioma: new trials by email Literature Review of Oligodendroglioma trials Research Report on Oligodendroglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma Safusidenib, Placebo - Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2 | Phase 3 | Not yet recruiting | Nuvation Bio Inc. | 140 | 2027-03-01 | 2026-07-17 |
| Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study Safusidenib - Glioma : Oligodendroglioma or Astrocytoma | Phase 2 | Not yet recruiting | University of Zurich | 20 | 2027-03-01 | 2026-09-21 |
| Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease Safusidenib - Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma | Phase 2 | Recruiting | Nuvation Bio Inc. | 40 | 2027-03-01 | 2026-10-20 |
| A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1) SRN-101 - Recurrent High Grade Gliomas, Glioblastoma (GBM) | Phase 1 / Phase 2 | Not yet recruiting | Siren Biotechnology | 40 | 2026-12-01 | 2026-10-28 |
| Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® GammaTile® - Glioma, Glioblastoma | Phase 2 | Not yet recruiting | University of California, Irvine | 20 | 2026-10-01 | 2026-09-23 |
| Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. Pre-radiation temozolomide. - High Grade Gliomas, Glioblastoma | Phase 2 | Recruiting | The Cooper Health System | 70 | 2026-07-13 | 2026-10-09 |
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Biospecimen Collection, Eflornithine, Lumbar Puncture - Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 33 | 2026-06-23 | 2026-06-24 |
| Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being Group Self-Management Sessions, Educational Materials Only - Brain Cancer | Not applicable | Not yet recruiting | University of Colorado, Denver | 64 | 2026-06-01 | 2026-06-05 |
| Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1 [C-11]-CS1P1, Brain MRI - Central Nervous System Cancer, Brain Metastases | Phase 2 | Recruiting | Washington University School of Medicine | 104 | 2026-04-16 | 2026-04-21 |
| HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer) HOBSCOTCH-CA - Brain Cancer, Brain Tumor | Not applicable | Recruiting | Dartmouth-Hitchcock Medical Center | 125 | 2025-11-03 | 2025-11-21 |
| Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma exHSC, Nivolumab, Resection or biopsy - Recurrent High-grade Glioma, Grade III Astrocytoma | Phase 1 | Active not recruiting | University of Florida | 12 | 2025-07-25 | 2026-09-23 |
| Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR) IDH-mutant Glioma (Oligodendroglioma, Astrocytoma) | Recruiting | LMU Klinikum | 100 | 2025-07-17 | 2025-09-08 | |
| FearLess in NeuroOncology Fearless in Neuro-Oncology - Primary Malignant Brain Tumor, Glioblastoma (GBM) | Not applicable | Recruiting | Virginia Commonwealth University | 112 | 2025-06-24 | 2026-09-09 |
| Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age SIACI of cetuximab and bevacizumab - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 / Phase 2 | Recruiting | University of Miami | 20 | 2025-06-19 | 2025-12-08 |
| Study of Olutasidenib and Temozolomide in HGG Olutasidenib + TMZ - High Grade Glioma, Astrocytoma | Phase 2 | Recruiting | Rigel Pharmaceuticals | 60 | 2025-02-01 | 2026-09-01 |
| Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401) 5-Aminolevulinic acid Hydrochloride (Gliolan®), CV01 - Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO) | Phase 1 | Completed | Universität Münster | 16 | 2025-01-27 | 2026-02-27 |
| Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy Assessment, Questionnaire Administration, Telemedicine Visit - Astrocytoma, IDH-Mutant, Glioblastoma | Phase 4 | Completed | Mayo Clinic | 30 | 2024-10-07 | 2026-04-29 |
| ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients TTRNA-DC vaccines with GM-CSF, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT - Recurrent Oligodendroglioma, Progressive Oligodendroglioma | Phase 1 | Recruiting | University of Florida | 12 | 2024-09-19 | 2026-10-30 |
| CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial Cognitive Behavioral Therapy for Insomnia - Primary Brain Tumor, Glioblastoma | Phase 2 | Completed | Virginia Commonwealth University | 70 | 2024-07-08 | 2025-10-01 |
| Investigational Imaging Technique During Brain Surgery Craniotomy, Quantitative Oblique Back-Illumination Microscopy - Astrocytoma, Glioblastoma | Not applicable | Suspended | Emory University | 24 | 2024-03-11 | 2026-04-24 |
Showing 20 of 411. Sign in to see all of them.
Astrocytoma (377) · Glioblastoma (264) · Glioma (242) · Brain Neoplasms (212) · Central Nervous System Neoplasms (179) · Gliosarcoma (176) · Ependymoma (96) · Medulloblastoma (88) · Choroid Plexus Neoplasms (61) · Optic Nerve Glioma (56) · Meningioma (52) · Familial ependymoma (51) · Neuroectodermal Tumors, Primitive (44) · Glioma, Subependymal (43)
Neoplasms by Histologic Type (409) · Neoplasms, Glandular and Epithelial (409) · Neoplasms, Nerve Tissue (409) · Neuroectodermal Tumors (408) · Neoplasms, Germ Cell and Embryonal (405) · Neoplasms, Neuroepithelial (398) · Neoplasms (391) · Neoplasms by Site (310) · Nervous System Diseases (310) · Nervous System Neoplasms (308) · Central Nervous System Diseases (266) · Brain Diseases (261) · Glioma (169) · Central Nervous System Neoplasms (127) · Cranial Nerve Diseases (63)
Temozolomide (74) · Radiotherapy (34) · Carboplatin (21) · Bevacizumab (18) · Magnetic Resonance Spectroscopy (17) · Carmustine (16) · Irinotecan (16) · Vincristine (14) · Filgrastim (13) · Surgical Procedures, Operative (13) · Procarbazine (10) · Cyclophosphamide (8) · Erlotinib Hydrochloride (8) · Etoposide (7) · Lomustine (7)
National Cancer Institute (NCI) (56) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (22) · Duke University (21) · Pediatric Brain Tumor Consortium (14) · City of Hope Medical Center (12) · Wake Forest University Health Sciences (11) · Children's Oncology Group (10) · Jonsson Comprehensive Cancer Center (10) · European Organisation for Research and Treatment of Cancer - EORTC (9) · Memorial Sloan Kettering Cancer Center (8) · National Institutes of Health Clinical Center (CC) (8) · M.D. Anderson Cancer Center (7) · New Approaches to Brain Tumor Therapy Consortium (7) · Case Comprehensive Cancer Center (6) · Northwestern University (6)
United States (337) · Canada (35) · United Kingdom (20) · France (19) · Netherlands (19) · Germany (18) · Switzerland (17) · Australia (15) · Belgium (12) · Italy (12) · Austria (8) · China (8) · Spain (7) · Denmark (6) · New Zealand (6)
Stuart A. Grossman, MD (9) · Henry S. Friedman, MD (8) · Darell D. Bigner, MD, PhD (6) · Edward G. Shaw, MD (6) · Howard A. Fine, MD (5) · Asha Das, MD (4) · David A. Reardon, MD (4) · Jana Portnow (4) · Jeffrey Raizer, MD (4) · Susan M. Chang, MD (4) · David A. Walker (3) · Edward Pan, MD (3) · Elizabeth Fox, MD (3) · Glenn J. Lesser, MD (3)
PMID 23377664, PMID 35731991, PMID 11410496, PMID 11586105, PMID 11772431, PMID 12649108, PMID 12721262, PMID 12829671, PMID 14586216, PMID 14670747, PMID 14769140, PMID 15292713, PMID 15514370, PMID 15565574, PMID 16012795, PMID 16061868, PMID 16133802, PMID 16192602, PMID 16200343, PMID 16234526, PMID 16533779, PMID 16533878, PMID 16549835, PMID 16782910, PMID 16782911, PMID 16817692, PMID 16863926, PMID 16914576, PMID 16914578, PMID 17264335, PMID 17317837, PMID 17470857, PMID 17549014, PMID 17610262, PMID 17634493, PMID 17694310, PMID 17941066, PMID 18048828, PMID 18056189, PMID 18056194, PMID 18089866, PMID 18089867, PMID 18094423, PMID 18182667, PMID 18281544, PMID 18359865, PMID 18371182, PMID 18470481, PMID 18477765, PMID 18543042
U01CA081457 (15), P30CA033572 (8), U01CA062399 (7), U01CA062475 (7), U10CA098543 (5), P30CA006973 (4), P30CA043703 (4), U01CA137443 (4), P30CA008748 (3), U01CA097452 (3), U10CA081851 (3), U10CA081920 (3), U10CA180868 (3), UM1CA081457 (3), 2023 (2)